{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-035099","form_type":"8-K","ticker":"PCSA","cik":"0001533743","company_name":"Processa Pharmaceuticals, Inc.","filed_at":"2026-07-29T11:35:23+00:00","discovered_at":"2026-07-29T11:40:01.539356+00:00","generated_at":"2026-07-29T11:40:36.544686+00:00","sec_items":["1.01","5.03","1.02","2.01","3.02","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Processa completes reverse merger with Vidya, raises $200M PIPE, terminates Elion license","bullets":["Merger closed: Processa issues 558,398 common + 142,744 Series A Preferred (convertible 1:1,000) to Vidya holders.","Raises $200M via PIPE of 163,775 Series A Preferred shares; closing expected July 30, 2026.","Proceeds to fund operations into H2 2029 and Phase 2 studies for food allergy, CSU, and RMS.","Terminates Elion license for PCS6422; pays $650K in fees, returns program, grants 7.5% equity in NewCo.","Sheila Gujrathi, Vidya founder, appointed to board; existing Processa holders diluted to ~0.9% post-PIPE."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-035099","json":"https://secwatch.observer/filing/0001493152-26-035099.json","markdown":"https://secwatch.observer/filing/0001493152-26-035099.md","text":"https://secwatch.observer/filing/0001493152-26-035099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533743/000149315226035099/0001493152-26-035099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533743/000149315226035099/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T11:40:36.544686+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}